Browse
···
Log in / Register

Owner Services Manager (Koloa)

Negotiable Salary

WG5G+82 Omao, HI, USA

Favourites
Share

Description

Parrish Kauai is expanding and seeking a self-motivated, team-oriented professional to join our property management team. The position is responsible for delivering exceptional service to property owners while also overseeing the day-to-day operations and project management of a portfolio of vacation rental homes. Core responsibilities include managing property projects, ensuring each property is consistently well-maintained and presented at the highest standard, and building strong, positive relationships with owners, guests, and vendors. Strong leadership, organizational, and communication skills are essential, along with the ability to multitask, manage projects to completion, and provide a seamless owner experience. Salary is based on experience. Weekend and holiday availability is required.

Source:  craigslist View original post

Location
WG5G+82 Omao, HI, USA
Show map

craigslist

You may also like

Craigslist
Research Study for Adults with First Episode/Early Phase Schizophrenia (Chicago)
Hello, I wanted to let you know about a study that is taking place at our clinic. This study is sponsored by Vanguard Research Group and our clinic is one of the research sites helping them with this study. What is the purpose of this study? Schizophrenia is a condition that negatively affects people’s mental health in different ways. For example, it can affect a person’s mood, behavior, or cognition. Cobenfy is a new FDA approved drug for the treatment of the positive symptoms of schizophrenia. Cobenfy is different from other antipsychotics as it has a new “mechanism of action” compared to all other antipsychotics approved from the treatment of schizophrenia at this time. Since Cobenfy is the first medication of its drug class to be FDA approved for schizophrenia, researchers are interested to know how this new class of antipsychotics affects those with early phase schizophrenia specifically. This clinical trial will test if Cobenfy can help improve the positive symptoms of patients with first episode/early phase schizophrenia, better than other antipsychotics. To be eligible to participate, you must: ❖ Be at least 18 years or older ❖ Have a primary diagnosis of schizophrenia ❖ Have been on a stable dose of 1 antipsychotic medication for at least 8 weeks before treatment with no dose changes within the last 4 weeks. ❖ Have started your first antipsychotic treatment within the past 5 years. Patients who meet eligibility criteria and enroll will come into our office to receive the study drug. Once enrolled, in-person clinic visits will occur every 1-4 weeks for about 24 weeks until the end of treatment visit, with a final follow-up visit 28 days after you last take the study drug (no more than 13 visits total). If you decide to participate, the study drug will be provided by/paid for by our clinic and study related assessments will be conducted during clinic visits. You may also be compensated for your participation and be reimbursed for any study-related travel. Want to learn more? If you or someone you know is interested in learning more about this research study, please feel free to contact us by calling 312-503-9092 or emailing. Thank you for your time and I hope to hear from you soon. Principal Investigator: Jeffrey Rado, MD STU00223950
187 E Pearson St, Chicago, IL 60611, USA
$100-125/day
Craigslist
Paid Research Study for People Diagnosed with Depression (Chicago)
Do you struggle with symptoms of depression? You may be able to take part in a research study. Some people experience decreased motivation, trouble finding enjoyment in everyday activities, and difficulty with sleep because of their depression. These challenges—known as symptoms of depression—can significantly affect daily life and overall well-being. Unfortunately, the medications available don’t always fully relieve these symptoms. The OARS-7 Study is examining a new investigational medication added on to your current treatment to potentially provide additional support for individuals struggling with motivation and enjoyment and insomnia due to depression. What is the OARS-7 Study? The OARS-7 study is two parts. If you are eligible to take part in the study, you have the option to complete both parts. The first part is a randomized control trial of the study medication versus a placebo. The second part is an open label treatment phase for study medication and a second subsequent randomized control trial for study medication versus placebo. The results of this study could help other people who experience symptoms of depression and need additional support. Who can take part? You may qualify for the OARS-7 Study if you are: • Between the ages of 18-74 • Have a primary diagnosis of Major Depressive Disorder (MDD) • Have been on a stable dose of an antidepressant medication (SSRI/SNRI) • Are still experiencing symptoms of depression This research study is completely voluntary. If you qualify, you do not have to join the study, and if you do join, you can leave the study at any time. Interested? Contact us at: 312-503-7071 https://sites.northwestern.edu/mindtrials/research/current-trials-for-depression/ Principal Investigator: Jeffrey Rado, MD STU00223008
187 E Pearson St, Chicago, IL 60611, USA
$150/day
Cookie
Cookie Settings
Our Apps
Download
Download on the
APP Store
Download
Get it on
Google Play
© 2025 Servanan International Pte. Ltd.